Anti-HA Antibody Market Analysis

Type (IgM, IgG, IgA)

The IgM segment in the anti-HA antibody market is expected to hold 47% of the revenue share during the forecast period owing to the implementation of this type of anti-HA antibody in different medications. For instance, in mice, a singular intranasal dose of IgM-14 at 0.044 mg per kg body weight provides prophylactic efficiency and a single dose at 0.4 mg per kg provides therapeutic efficiency against SARS-CoV-2. IgM-14, but not IgG-14, also provides powerful therapeutic protection against the P.1 and B.1.351 variants.  IgM anti-HA antibodies are mainly oriented against the HA molecule itself and can be spotted in the blood after detection of HA. These antibodies may help safeguard against disease by Haemophilus influenzae, a bacterium that can create respiratory infections.

Application (Therapeutic, Research, Diagnostic)

The diagnostic segment is estimated to account for 40% of the global anti-HA antibody market share by 2036 and is anticipated to expand at the highest rate over the forecast timeline owing to the wide utilization of blood tests for diagnostic reasons like Food Allergy & intolerance testing and immunoprotein diagnostic testing among others. For instance, as of December 22, 2022, Austria had executed the most antibody tests per one million population among the countries most massively influenced by the pandemic. The U.S. has executed over 1.1 billion antibody tests in total. Countries across the globe made prevalent testing a key part of their strategies to exit lockdown. However, the international requirement for antibody test kits has been massive. The kits are implemented to recognize antibodies in a person’s blood pattern. The existence of antibodies signifies the person has been susceptible to the SARS-CoV-2 virus and created antibodies to help fight it.

Our In-Depth Analysis of the Global Market Includes the Following Segments: